You are here

  • Home
  • Archive
  • Volume 15, Issue 2
  • Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality

Article info

Article menu
Download PDFPDF
Therapeutics
Systematic review
Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality

Authors

  1. Correspondence to Professor Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel; altenen{at}post.tau.ac.il
View Full Text

Citation

Tenenbaum A, Fisman EZ
Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality
BMJ Evidence-Based Medicine 2010;15:52-53.

Publication history

  • First published May 1, 2010.
Online issue publication 
October 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions